

THORACIC MALIGNANCIES: 2018 INSIGHTS

Tirano (SO)
3 marzo 2018

PROGRAMMA SCIENTIFICO

8.30 Registration

First session - Immunopathology

Chair: *Silvio Veronese, Paolo Declich*

Predictive factors for IO: PDL1 IHC vs TMB vs PDL1 IHC+TMB

9.00 Pathologist perspective
Umberto Malapelle

9.15 Oncologist perspective
Luca Toschi

9.30 Discussion

Second Session - Immunotherapy and its role in “early” and “late” stage NSCLC

Chair: *Paolo Bidoli, Mauro Palazzi, Gerolamo Rossi*

9.45 **The Ios indication in advanced NSCLC: perspective?**
Francesco Grossi

IO in neo/adjuvant setting: wath is its role

10.00 Surgeon perspective
Luca Bertolaccini

10.15 Oncologist perspective
Alessandra Bearz

10.30 **Combining radiotherapy with immune-checkpoint inhibitors: safety and activity**
Davide Franceschini

10.45 Discussion

Third Session - Oncogene addiction: therapeutic strategy

Chair: *Nicoletta Zilembo, Adolfo Favaretto*

11.00 EGFR: sequence or third gen TKIs up front
Marcello Tiseo

11.15 ALK: sequence or second/third gen TKIs up front
Enrica Capelletto

11.30 Discussion

Other OMAs: NGS discovery and its impact in clinical practice

Coordinator: *Vanesa Gregorc*

11.45 Pros

Angelo Delmonte

12.00 Contra

Martina Imbimbo

12.15 Discussion

Point of view

The tumor, the host and their links

Diego Cortinovia

Discussion: *Roberta Buosi*

13.00 Lunch

Fourth Session - MPM and other issues

Chair: *Alessandro Del Conte*

MPM new avenues understanding the biology

Coordinator Discussant: *Giovanni Luca Ceresoli*

14.00 Molecular targets

Giulio Cerea

14.15 Immunotherapy

Matteo Brighenti

14.30 Discussion

The adverse events of active treatments

14.45 Opioids AEs: practical management

Raffaele Giusti

15.00 Lung toxicity: its impact and clinical relevance

Clelia Casartelli

15.15 Financial toxicity: true sustainability

Alessandro Follador

15.30 Discussion and closing remarks

SCIENTIFIC BOARD

Enrica Capelletto - A.O.U. San Luigi Gonzaga, Orbassano (TO)

Diego Cortinovis - A.O. S. Gerardo, Monza (MB)

Marcello Tiseo - A.O.U. Parma

Giuseppe Valmadre - ASST Valtellina e Alto Lario

FACULTY

Alessandra Bearz - Centro di Riferimento Oncologico, Aviano (PN)

Luca Bertolaccini - AUSL Romagna, Ravenna

Paolo Bidoli - A.O. S. Gerardo, Monza (MB)

Matteo Brighenti - A.O. Istituti Ospitalieri, Cremona

Roberta Buosi - Ospedale Santo Spirito, Casale Monferrato (AL)

Enrica Capelletto - A.O.U. San Luigi Gonzaga, Orbassano (TO)

Clelia Casartelli - Ospedale Valduce, Como

Giulio Cerea - Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano

Giovanni Luca Ceresoli - Humanitas Gavazzeni, Bergamo

Diego Cortinovis - A.O. S. Gerardo, Monza (MB)

Paolo Declich - ASST Valtellina e Alto Lario

Alessandro Del Conte - ASS 5 - Friuli Occidentale - P.O. di Pordenone

Angelo Delmonte - IRCCS-Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC)

Adolfo Favaretto - Azienda ULSS 9 Treviso

Alessandro Follador – A.O.U. S. M. Misericordia, Udine

Davide Franceschini - Istituto Clinico Humanitas-Humanitas Cancer Center, Rozzano (MI)

Raffaele Giusti – A.O. Sant'Andrea, Roma

Vanesa Gregorc – Ospedale San Raffaele, Milano

Francesco Grossi - IRCCS AOU San Martino IST – Istituto Nazionale per la Ricerca sul Cancro, Genova

Martina Imbimbo - Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Umberto Malapelle - Azienda Universitaria Policlinico-Università degli Studi di Napoli Federico II, Napoli

Mauro Palazzi - ASST-Grande Ospedale Metropolitano Niguarda, Milano

Gerolamo Rossi - Ospedale Valduce, Como

Marcello Tiseo - A.O.U. Parma

Luca Toschi - Istituto Clinico Humanitas-Humanitas Cancer Center, Rozzano (MI)

Silvio Veronese - ASST-Grande Ospedale Metropolitano Niguarda, Milano

Nicoletta Zilembo - Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milano